SCHEMBL7089602

SCHEMBL7089602

c1ccc2c(-c3ccc4[nH]ccc4c3)cccc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.59
GUSB P08236 3/20 0.49
MAP3K11 Q16584 3/20 0.49
CASP3 P42574 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
HCRTR1 O43613 1/20 0.49
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
TRPA1 O75762 1/20 0.47
ITGB2 P05107 1/20 0.47
ICAM1 P05362 1/20 0.47
ITGAL P20701 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
AHR P35869 1/20 0.47
ADK P55263 1/20 0.47
PIK3CD O00329 2/20 0.47
PIK3CB P42338 2/20 0.47
PIK3CG P48736 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27534537 0.98 NPC1 (0.57) NPC1GUSBMAP3K11CASP3SENP7
SCHEMBL12223921 0.89 NPC1 (0.57) NPC1GUSBMAP3K11CASP3SENP7
SCHEMBL8995170 0.87 PIK3CD (0.51) NPC1CA1CA2TRPA1ITGB2
SCHEMBL7088454 0.85 PIK3CD (0.62) NPC1GUSBMAP3K11CASP3SENP7
SCHEMBL15810995 0.81 NPC1 (0.53) NPC1GUSBMAP3K11CASP3SENP7
SCHEMBL22178786 0.81 NPC1 (0.76) NPC1GUSBMAP3K11CASP3SENP7
SCHEMBL16918805 0.79 NPC1 (0.62) NPC1GUSBMAP3K11CASP3SENP7
SCHEMBL12224208 0.79 NPC1 (0.50) NPC1GUSBMAP3K11CASP3SENP7
SCHEMBL940968 0.79 MAP3K11 (0.58) NPC1MAP3K11CASP3SENP7SENP6
SCHEMBL22649086 0.78 ALOX5 (0.57) NPC1GUSBMAP3K11CASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1092765-A New tryptamine analogues and preparation method thereof and purposes SMITHKLINE BEECHAM PLC (GB) 1994-09-28 CN claimed
US-20030203959-A1 Novel modulators of potassium channels 4SC AG (DE) 2003-10-30 US disclosed
EP-0674620-A1 TRYPTAMINE ANALOGUES AS 5-HT 1?-LIKE AGONISTS SMITHKLINE BEECHAM PLC (GB) 1995-10-04 EP disclosed
CN-1092765-A New tryptamine analogues and preparation method thereof and purposes SMITHKLINE BEECHAM PLC (GB) 1994-09-28 CN disclosed
WO-1994014771-A1 TRYPTAMINE ANALOGUES AS 5-HT1-LIKE AGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203959-A1 Novel modulators of potassium channels HCN3, KCNN3, KCNN1 NPC1 487/4885GUSB 3930/4885MAP3K11 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.